NCT05360966 - Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3) | Biotech Hunter

Enrollment

467

Participants

Timeline

Start Date

July 18, 2022

Primary Completion Date

October 17, 2023

Study Completion Date

October 17, 2023

Conditions

Dry Eye Disease

Interventions

DRUG

0.003% AR-15512 ophthalmic solution

Administered via topical ocular instillation

DRUG

AR-15512 vehicle ophthalmic solution

Inactive ingredients administered via topical ocular instillation

Trial Locations (23)

14624

NVision Clinical Research, LLC, Rochester

16507

Erie Retina Research, Erie

23230

Virginia Eye Institute, Richmond

24502

Piedmont Eye Center, Lynchburg

27529

Oculus Research, Garner

28227

Pure Ophthalmic Research, Mint Hill

28451

Wilmington Eye, Leland

33904

Argus Research Center, Cape Coral

47203

Pankratz Eye Institute, Columbus

60046

Jackson Eye, Lake Villa

60062

Wyse Eyecare, Northbrook

75243

Axis Clinicals, Dallas

78731

Keystone Research, Austin

89123

AdvanceMed Clinical Research, Las Vegas

90505

NVision Clinical Research, LLC, Torrance

91325

Shultz Vision, Northridge

92663

Eye Research Foundation, Newport Beach

92835

NVision Clinical Research, LLC, Fullerton

95926

Reeve Woods Eye Center, Chico

01810

Andover Eye Associates, Andover

01757

Boston Vision, Milford

02767

Andover Eye Associates - Raynham, Raynham

02886

Andover Eye Associates, Warwick